Fidaxomicin Patent Expiration
Fidaxomicin is Used for treating Clostridioides difficile-associated diarrhea in patients 6 months of age and older. It was first introduced by Cubist Pharmaceuticals Llc
Fidaxomicin Patents
Given below is the list of patents protecting Fidaxomicin, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Dificid | US7378508 | Polymorphic crystalline forms of tiacumicin B | Jul 31, 2027 | Cubist Pharms Llc |
| Dificid |
US7378508 (Pediatric) | Polymorphic crystalline forms of tiacumicin B | Jan 31, 2028 | Cubist Pharms Llc |
| Dificid | US7863249 | Macrolide polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof | Jul 31, 2027 | Cubist Pharms Llc |
| Dificid | US7863249 | Macrolide polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof | Jul 31, 2027 | Cubist Pharms Llc |
| Dificid |
US7863249 (Pediatric) | Macrolide polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof | Jan 31, 2028 | Cubist Pharms Llc |
| Dificid | US7906489 | 18-membered macrocycles and analogs thereof | Mar 04, 2027 | Cubist Pharms Llc |
| Dificid |
US7906489 (Pediatric) | 18-membered macrocycles and analogs thereof | Sep 04, 2027 | Cubist Pharms Llc |
| Dificid | US8586551 | 18-membered macrocycles and analogs thereof |
Jul 15, 2023
(Expired) | Cubist Pharms Llc |
| Dificid | US8586551 | 18-membered macrocycles and analogs thereof |
Jul 23, 2023
(Expired) | Cubist Pharms Llc |
| Dificid |
US8586551 (Pediatric) | 18-membered macrocycles and analogs thereof |
Jan 15, 2024
(Expired) | Cubist Pharms Llc |
| Dificid | US8859510 | Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof | Jul 31, 2027 | Cubist Pharms Llc |
| Dificid |
US8859510 (Pediatric) | Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof | Jan 31, 2028 | Cubist Pharms Llc |
| Dificid | US9808530 | Composition of tiacumicin compounds | May 28, 2034 | Cubist Pharms Llc |
| Dificid |
US9808530 (Pediatric) | Composition of tiacumicin compounds | Nov 28, 2034 | Cubist Pharms Llc |
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳
Fidaxomicin Generics
Only one generic application has been filed for Fidaxomicin.
Given below is the list of companies who have filed for Fidaxomicin generic.
1. ACTAVIS LABS FL
Actavis Laboratories Fl Inc An Indirect Wholly Owned Sub Of Teva Pharmaceuticals Usa Inc has filed for 1 generic for Fidaxomicin. Given below are the details of the strengths of this generic introduced by Actavis Labs Fl.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 200MG | tablet | Prescription | ORAL | AB | Jan 16, 2024 |